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Abstract
Background: Elevations of serum prolactin (PRL) are associated with an increased risk for breast
cancer. PRL signaling through its prolactin receptor (PRLr) involves the Jak2/Stat5 pathway.
Luciferase-based reporter assays have been widely used to evaluate the activity of this pathway.
However, the existing reporters are often not sensitive enough to monitor the effect of PRL in this
pathway.
Results: In this study, a new biologically relevant reporter, pGL4-CISH, was generated to study
the PRL/Jak2/Stat5 signaling pathway. The sensitivity of pGL4-CISH to detect PRL was superior to
that of several other commonly utilized Stat5-responsive reporters. Interestingly, the enhanced
function pGL4-CISH was restricted to the estrogen receptor positive (ER+) human breast cancer
cell lines T47D and MCF7, but not in the ER-MDA-231, BT-474, or MCF10A cell lines.
Overexpression of Stat5 further enhanced the effect of PRL on pGL4-CISH.
Conclusion: These studies demonstrate that pGL4-CISH is a novel and sensitive reporter for
assessing the activity of the PRL/Stat5 signaling pathway in the ER+ human breast cancer cells.
Background
Prolactin (PRL) is a 22 kDa hormone that stimulates the
growth and differentiation of mammary epithelium, and
initiates and maintains lactation [1-3]. PRL serum levels
range from 5–20 ng/ml in blood in non-pregnant humans
and up to 200 ng/ml in pregnant females. The lactogenic
actions of PRL are mediated by binding to its receptor
(PRLr), an event that activates several proximal PRLr sign-
aling cascades including Jak2-Stat5 [4-8]. PRL-induced
autophosphorylation of Jak2 results in the activation of
this tyrosine kinase, and its subsequent phosphorylation
of both the PRLr and the PRLr-associated, latent transcrip-
tion factor Stat5. Following phosphorylation, Stat5 is
released from the PRLr, self-dimerizes and is translocated
into the nucleus [6,9-11], where it binds to gene promoter
sequences containing Stat5-binding elements, resulting in
the induction of gene expression such as Cytokine Induc-
ible SH2-containing protein (CISH or CIS), β-casein, c-
Myc, and cyclin D1 [9,12,13].
The Jak2/Stat5 pathway is negatively regulated by a feed-
back loop through the suppressors of cytokine signaling
[13,14], a family of related proteins that includes CISH.
The induction of CISH gene expression results in the bind-
ing of CISH to the phosphorylated PRLr, which in turn
prevents the subsequent binding of Stat5 to PRLr, hence
attenuating the PRL/Stat5 signaling pathway [15]. Inter-
estingly, while blocking Stat5 activation CISH does not
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stop continued Jak2 and MAPK activity. This observation,
coupled with the detection of elevated expression of CISH
protein in primary human breast cancers, has led to the
hypothesis that PRL-induced CISH expression may facili-
tate the pathogenesis of breast cancer by enhancing cell
proliferation triggered by Jak2/MAPK activity at the
expense of cell differentiation mediated by Stat5 [16].
Luciferase-reporter assays are widely used to monitor the
cellular events related to transduction and gene expres-
sion regulated by specific signaling cascades, such as PRL/
Jak2/Stat5 pathway. There are several reporter construct
used to study Stat5 activity, such as the LHRE-TK-luc [17],
cyclin D1∆-944 [12,18,19], β-casein-344 [20], and β-
casein-2300 [21]. However, in breast cancer cells these
existing reporter constructs have proven to be relatively
insensitive to the effects of PRL, requiring supra-physio-
logic concentrations of PRL (>200 ng/ml) to detect
reporter induction. To generate a more PRL-sensitive
reporter construct, our analysis of the literature suggested
that the PRL-responsive CISH promoter could be an opti-
mal candidate as it contains four Stat5 binding sites, and
is rapidly activated after PRL stimulation [22]. Cloning of
the promoter region of the CISH gene into the improved
pGL4.10 luciferase reporter construct resulted in a highly
sensitive, PRL-responsive reporter that should be of wide-
spread utility in examining PRL/Stat5 pathway in ER+
human breast cancer cells.
Methods
Cell lines, reagents and vectors
The breast cancer cell lines T47D, MCF7, BT-474, MDA-
231 and the non-tumorigenic epithelial cell line MCF10A
from American Type Culture Collection (ATCC) were
maintained in Dulbecco's modified Eagle's medium
(DMEM) or the similar growth medium supplemented
with 10% fetal bovine serum (FBS) and penicillin/strepto-
mycin (Pen/Strep 50 ug/ml) in a humidified atmosphere
of 5% CO2 at 37°C. Human recombinant prolactin was
obtained from Dr. Michael Hodsdon (Yale University)
[23]. Transfection reagents Fugene HD (Roche, Indianap-
olis, IN) for MCF7 cells and Lipofactamine 2000 (Invitro-
gen, Casbad, CA) for all other cell lines were used for
transfection. Vectors Renilla luciferase reporter pGL4.73
(Promega), pGL4.10 (Promega), pGL4-CISH (this study,
description below), pEF-PRLr [24], and pEF V5/His A
(Invitrogen) were used for transfection.
Reporter construction
The CISH promoter region (-1034 to +1) was PCR amplified
using the primers olg104 5'CCGCCC CAACCTCTATCA-3'
and olg110 5'-GGCCAAGCTTACTGAGAGGCAGTGGCG
CGGACCGCC-3' (the bold sequence is a HindIII restriction
site) using HiFi PCR kit (Invitrogen). For the vector, a pro-
moter-less pGL4 luciferase expression construct (Promega,
Madison, WI) was utilized. The EcoRV and HindIII digested
pGL4.10 reporter and the HindIII digested PCR product were
ligated and transformed into TOP10 E coli cells. The con-
struct was confirmed by sequencing using primer olg18 (5'-
CCGTCTTCGAGTGGGTAGAAT-3') and RVprimer 3
(Promega). The generated reporter was termed pGL4-CISH.
The cyclin D1 promoter region was PCR amplified using the
olg88 (5'-ATTGGGTACCTAAATCCCGGGGGACCCA CT-3',
the bold sequence is a KpnI restriction site) and olg89 (5'-
CCGGAAGCTTGGAGGCTC CAGGACTTTGCA-3', the bold
sequence is a HindIII restriction site). The KpnI and HindIII
digested PCR product and pGL4.10 reporter backbone were
ligated and the construct was named as pGL4-CCND300.
Transfection and dual luciferase assay
T47D cells were plated in a 24-well plate and grown at
60% confluency for transfection. For luciferase assays, 50
ng of a given reporter construct, 0.5 ng of renilla (pGL4.73
from Promega) and/or 250 ng of pCMV-wtStat5a per well
were used for transfection. After transfection, cells were
maintained in 500 ul of growth media overnight, and
then arrested in 200 ul of serum-free, phenol red-free
DMEM for 24 hours followed by PRL treatment for 24
hours. After treatment, cells were lysed in 120 ul of 1 ×
passive lysis buffer (PLB buffer from Promega) at room
temperature for 15 minutes. For dual luciferase assay, 25
ul of lysate was aliquoted into a 96-well plate and sub-
jected to analysis of firefly luciferase (50 ul of LAR II) and
renilla (50 ul of stop and glow buffer). Luminescence was
read on Victor3 1420 Multilabel Counter (Perkin Elmer,
Waltham, MA). All analyses were performed in duplicate,
with each experiments performed at least twice.
Western blot
Forty microliters of cell lysates from luciferase assay were
loaded onto 10% SDS-PAGE gel. Proteins were transferred
onto PVDF membrane and western blots were performed
using 50% skim milk (1:1 ratio of skim milk and 1 × TBS).
Antibodies anti-Stat5a (Zymed, 71–2400, 1:2000 dilu-
tion), anti-PRLr (Zymed, 35–9200, 1:2000 dilution) and
anti-GAPDH (Zymed, 39–8600, 1:2000 dilution) were
used for Western blot analysis. Images were obtained
using a Fujifilm LAS-3000 image analyzer.
Results
At present, there are several reporters available for the
study of the Stat5 signaling pathway, that includes a syn-
thetic reporter with six-tandem Stat5 responsive elements
(LHRE-TK-luc), as well as reporter constructs containing
the promoter regions from PRL-responsive genes, namely
two cyclin D1 promoter-derived sequences (pGL4-
CCND300 and the cyclin D1∆-944 reporters containing
300 bp and 944 bp of the cyclin D1 promoter), and the rat
β-casein promoter sequences (β-casein-344 and β-casein
2300) (Fig 1A and Table 1). All of these reporters com-BMC Biotechnology 2008, 8:11 http://www.biomedcentral.com/1472-6750/8/11
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monly carry one or more Stat5 responsive elements and
have been widely used to study the PRL-induced activa-
tion of Stat5 pathway (Fig. 1A and Table 1). However as
noted above, they are relatively insensitive to the effect of
PRL.
CISH is a repressor through a negative feedback mecha-
nism in the Jak2/Stat5 pathway [15]. A web-based soft-
ware (TFsearch) was used to search for Stat5 binding sites
in the CISH promoter region, and found four Stat5 bind-
ing sites in the proximal region (Fig. 1A). In order to eval-
uate the response of the human CISH promoter in the
context of the Stat5/Jak2 signaling pathway, a 1034 bp
fragment (-1034 to +1) was cloned into upstream of a
luciferase reporter gene in the promoterless pGL4.10
reporter, resulting in a novel reporter construct termed as
pGL4-CISH. Initial use of this reporter in T47D cells
revealed that the construct was highly responsive to PRL.
To evaluate the luciferase signal strength as a function of
the quantity of transfected pGL4-CISH reporter, varying
concentrations of the pGL4-CISH reporter DNA (0–200
ng/1 × 105 cells per well in a 24-well plate) were trans-
fected into T47D cells. These studies revealed that 50 ng of
pGL4-CISH DNA resulted in a ~50% maximal lumines-
cence signal intensity in the presence of PRL (Fig 2A and
2B). To further optimize the pGL4-CISH reporter assay,
the response of this construct to different concentrations
of PRL was tested. Results indicated that pGL4-CISH was
induced 2-fold with 1 ng/ml of PRL, 8-fold with 10 ng/ml
of PRL, saturating at 200 ng/ml of PRL (Fig 2C). Addi-
tional time course analysis revealed a relatively rapid 4-
fold induction of the pGL4-CISH reporter after as short as
6 hours of PRL treatment (Fig 2D).
The response of the pGL4-CISH in human breast epithe-
lial lines was assessed by its transection into a panel of
ER+ and ER- cell lines. The ER+ breast cancer cell lines
T47D, MCF7, the ER- MDA-231, BT-474 and the non-
tumorigenic epithelial cell line MCF10A were chosen for
varying levels of PRLr expression (relative PRLr expres-
sion: T47D>MCF7>BT-474≈ MDA-231≈ MCF10A)
[25,26]. Results showed that robust expression of pGL4-
CISH was obtained in T47D transfectants (Fig 3A). In
MCF7 transfectants, pGL4-CISH was increased 2.1 fold
following PRL stimulation. No significant increase in
expression from the pGL4-CISH reporter was noted fol-
lowing PRL stimulation in the MCF10A, MDA231 or
BT474 cell lines (Fig 3A). As the responsiveness of the
pGL4-CISH reporter may be related to PRLr expression,
the response of this reporter in MCF7 transfectants over-
expressing the human PRLr was tested. Overexpression of
PRLr enhanced the PRL-induced response of pGL4-CISH
in MCF7 cells (Fig 3B and 3C), suggesting that PRLr levels
contributed to the responsiveness of the pGL4-CISH
expression in MCF7 cells.
To assess the sensitivity of pGL4-CISH reporter in T47D
cells, in contrast to other commonly utilized PRL-respon-
sive expression constructs such as LHRE-TK-luc, Cyclin
D1∆-944, pGL4-CCND300 and β-casein-2300 reporters,
direct comparisons of PRL-induced luminescence of T47D
transfectants were performed. As shown in Fig 4A, pGL4-
CISH had the highest basal luciferase activity (17000
units) compared to LHRE-TK-luc (150 units), beta-casein-
2300 (180 units), pGL4-CCND300 (6700 units) and Cyc-
lin D1∆-944 (410 units) (Fig 4A). Despite this higher level
of basal luciferase activity seen with pGL4-CISH, the over-
all PRL-induced expression from the pGL4-CISH reporter
was markedly increased over the other reporter constructs
evaluated. The pGL4-CISH luciferase activity was robustly
induced by 19-fold following PRL stimulation, while all
Promoter regions from commonly used reporters to evalu- ate the PRL/Jak2/Stat5 pathway Figure 1
Promoter regions from commonly used reporters to 
evaluate the PRL/Jak2/Stat5 pathway. Stat5 binding 
sites are indicated by filled circles.
CISH 1034 bp luc
luc
-1034
Cyclin D1 luc
-944
Beta-casein-2300 luc
-2300 +487 +1
+137
+1
Cyclin D1 luc
-300 +1 +1
pGL4-CISH
LHRE-TK-luc
Cyclin D1 -944
pGL4-CCND300
Beta-casein-2300
-250
Table 1: Comparison of Reporter Responses to PRL in T47D cells
Reporters DNA source Stat5 binding sites Sensitivity to PRL References
pGL4-CISH human 4 + + + this work
LHRE-TK-luc synthetic tandems 6 + + [17]
pGL4-CCND300 human 1 + this work
Cyclin D1∆-944 human 2 + [18]
Beta-casein-2300 rat 2 + + [21]
(+ + +, most sensitive; + +, sensitive; +, less sensitive in terms of reporter readout)BMC Biotechnology 2008, 8:11 http://www.biomedcentral.com/1472-6750/8/11
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of the other reporter only constructs showed a 2–3 fold
increase in luciferase expression at high physiologic con-
centration of PRL (100 ng/ml). The effect of increased
Stat5a levels on reporter responsiveness was also tested.
Results showed that the overexpression of Stat5a also
enhanced PRL induction of luciferase activity in all the
tested reporters, with pGL4-CISH showing the highest
responsiveness (Fig 4B + C). The dose responsiveness of
Stat5a on pGL4-CISH was also tested. As shown in Figure
4D, increasing expression of Stat5a did not alter the
reporter basal activity in the absence of PRL. However, in
the presence of PRL, pGL4-CISH luciferase activity
increased as a function of quantity of transfected Stat5a
(Fig 4D). Taken together, our data indicate that the
responsiveness of the pGL4-CISH reporter is sensitive to
both PRLr and Stat5a expression levels.
Discussion
The versatility and simplicity of the reporter assay is a
powerful tool in the fields of biological and pharmaceuti-
cal research [27], and there is an ongoing need for highly
responsive reporters [28]. Until recently, older reporter
vector backbones had spurious transcription factor bind-
ing sites resulting in both inaccurate and false-positive
results. For the studies presented here, a new pGL4
reporter with decreased cryptic DNA regulatory elements
and transcription factor binding sites was used as a back-
bone for reporter. We constructed a novel pGL4-CISH
reporter based on the pGL4 backbone and the Stat5-
The dose response and time course of pGL4-CISH to PRL in T47D breast cancer cells Figure 2
The dose response and time course of pGL4-CISH to PRL in T47D breast cancer cells. Following transfection of 1 
× 105 T47D cells with the pGL4-CISH and renilla control reporters, transfectants were cultured in minimal defined medium 
without FBS for 24 hours followed by 24 hours of PRL stimulation prior to luminescence assay. The pGL4.10 reporter back-
bone was used to compensate DNA amount used for transfection. A. Luciferase luminescence in PRL-stimulated T47D cells 
transfected with varying concentrations of pGL4-CISH reporter DNA (PRL concentration, 100 ng/ml). B. Fold changes of nor-
malized PRL-stimulated pGL4-CISH expression versus non-PRL-stimulated T47D transfectants as a function of transfected 
pGL4-CISH concentration (PRL concentration, 100 ng/ml). C. PRL dose response of expression of pGL4-CISH in T47D trans-
fectants. T47D cells were transfected with 50ng pGL4-CISH/1 × 105 cells, arrested and treated with PRL (100 ng/ml) for 24 
hours. D. Time course of pGL4-CISH expression in the presence of PRL (100 ng/ml).
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response-rich-element CISH promoter. The pGL4-CISH
DNA dose curve, PRL dose curve and time course param-
eters were optimized for this reporter. Our results indi-
cated that this reporter had a high sensitivity to PRL in
T47D, less so in MCF7, and little to none in ER- cell lines
evaluated. As subsequently shown with MCF7 cells, our
data would indicate that both PRLr and Stat5a levels con-
tribute to the responsiveness of the pGL4-CISH reporter.
Cell proliferation, as measured by 3H-thymidine incorpo-
ration, is a sensitive and simple way to test PRL action
[29]. In the T47D proliferation assay, maximal stimula-
tion (2.2-fold over basal levels, reaching a plateau) was
achieved with 100 ng/ml of PRL treatment [29]. In our
study, pGL4-CISH reporter demonstrated a 2-fold induc-
tion upon 1 ng/ml of PRL treatment, suggesting this
reporter was significantly more sensitive than the thymi-
dine-incorporated proliferation assay to detect breast can-
cer cell responsiveness to PRL stimulation.
The luciferase induction of pGL4-CISH, LHRE-TK-luc,
Cyclin D1∆-944, pGL4-CCND300 and Beta-casein2300
reporters was also compared in T47D cells. Results indi-
cated that pGL4-CISH reporter was the most responsive to
PRL treatment in T47D cells. A reporter termed -404CIS-
LUC containing about 500 bp of human CISH promoter
has also been reported [30]. However, this reporter dem-
onstrated poor PRL-induced expression in COS7 cells
[30]. We reason the different response to PRL of reporters
is due to the limited proximal promoter regions utilized,
the different backbones used for reporter construct, and
cells lines used for reporter assay.
PRL activates the latent cytoplasmic Stat5 by tyrosine
phosphorylation and dimerization in PRL/Jak2/Stat5
pathway [31]. The intranuclear phospho-Stat5 then acti-
vates the Stat5-responsive-gene expression. We observed
that in the absence of PRL, overexpression of Stat5a does
not stimulate pGL4-CISH luciferase. In the presence of
PRL, overexpression of Stat5 greatly enhanced the effect of
PRL on pGL4-CISH reporter (Fig 4D). These data indicate
that the activation of pGL4-CISH is influenced by the level
of available Stat5a following PRL treatment.
The pGL4-CISH reporter has potential applications in the
analysis of the PRL/Stat5 pathway, CISH promoter analy-
sis, and biological screening for drug discovery. Indeed, as
a novel bioassay for PRL, the pGL4-CISH reporter has a
sensitivity approaching that of the venerable rat Nb2 lym-
phoma cell bioassay for PRL. As a distinct advantage, the
PGL4-CISH system now provides a sensitive, species
homologous assay for the action of human PRL in human
cell lines expressing sufficient levels of PRLr and Stat5. The
CISH promoter has four Stat5 binding sites but also
Expression of pGL4-CISH to PRL and PRLr in different human breast cancer and epithelial cell lines Figure 3
Expression of pGL4-CISH to PRL and PRLr in different human breast cancer and epithelial cell lines. Cells were 
transfected with pGL4-CISH. After transfection, cells were arrested in minimal defined medium without FBS, the transfectants 
were stimulated with PRL for 24 hours prior to analysis of luminescence. A. Cells lines were transfected with 50 ng pGL4-
CISH/1 × 105 cells. B. MCF7 cells were overexpressed with pEF-PRLr and treated with PRL (200 ng/ml). *, P < 0.05. ***, P < 
0.001. C. The low inset is Western blot demonstrating PRLr overexpression level obtained with the various transfectants with 
the arrows indicating each lane of treatments. Error bars represent SEM; * denotes P < 0.05, and *** denotes P < 0.001 as com-
pared with no PRL stimulation alone.
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include other potential transcriptional binding sites such
as Sp1, HSF, c-Myb, and GATA-1. Detailed functional
mapping of this promoter to characterize the relative con-
tributions of cis-acting elements will improve our under-
standing of how PRL signaling triggers the response of the
CISH at the transcriptional level.
Conclusion
Given its sensitivity to PRL, the pGL4-CISH reporter
should be a useful tool in the screening of small com-
pound libraries in the identification of novel PRL/Stat5
inhibitors.
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